While we wait for some more news, I thought of putting the cat amongst the pigeons and........
Cheryl was a non executive director of Clarity - CU6. When it was announced she was to be the new CEO at Starpharma, she would of known what was happening behind the scenes at Clarity. The share price was $1.1o and the company's market capitalisation $287 million
Today the share price of Clarity is $4.60 as I type, and it's market capitalisations is $1.43 billion. The share price has shot up 318% over 7 months
No doubt Cheryl had done her due diligence on Starpharma before agreeing to take up the position of CEO. By the way for the short period of being on board of directors at CU6, it seems she never owned shares in that company.
The questions one needs to ask is why with the inside knowledge of both companies did she elect to walk away from Clarity and come to Starpharma
Starpharma's market capitalisation at time of announcement was around $50 million and it really has not changed that much since 10/10/23
Cheryl has now been with the company just over 4.5 months
She has been issued with 2,278,428 Performance Rights (SPLAK). Let us hope she is able to convert these performance rights into ordinary shares by the following, as was said at webinar and presented in slide deck
THE NEW KEY PERFORMANCE INDICATORS (KPI'S)
Maximising Dep® Asset Values
License deals and revenue generated
Accelerate Early Asset Development
Partnership and license conversions
Asset progression and milestone achievement
Build Long Term Sustainability
Marketed product sales
Total shareholder return
New Intellectual property (IP) created
SPL Price at posting:
11.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)